ABIVAX press release
Abivax includes the first patient in the United States in its global phase 3 program with obefazimod in ulcerative colitis.
First patient included in the United States in the global phase 3 program with obefazimod (“ABTECT Program”) for the treatment of moderate to severe ulcerative colitis (UC).
1,200 UC patients across 36 countries and 600 investigation centers will be included in the ABTECT program which includes two induction studies and a single maintenance study.
The 25 mg and 50 mg doses of obefazimod will be tested in patients naïve or refractory to advanced therapies.
The program is progressing as planned and the first results of the two induction studies are expected by the end of 2024.